一身白大褂，一边耐心询问村民的血压情况，一边在笔记本上记录基层诊疗中的所思所想——在福建不 少地方的县医院、基层卫生院，经常能看到全国政协委员、福建省高血压研究所所长谢良地的身影。对 他来说，这既是临床工作，也是作为政协委员的职责。 "硬件有了，人员也在，但专业能力和系统性还远远不够。"他坦言，基层医生往往"全科都管"，难以在 高血压等慢病防治上做专做细。为此，谢良地推动建立省、市、县三级高血压防控网络，通过"传帮 带"层层培训，让优质资源下沉，让基层医生有更系统的学习机会。 在谢良地看来，高血压的"防"比"治"更重要。几年前，他就建议将健康生活方式教育纳入小学教材，推 动在医疗机构、机场、车站等公共场所设置自助血压测量设备。"许多患者直到出现高血压并发症才就 医，往往为时已晚。早发现、早干预，才能真正减轻家庭和社会负担。"谢良地说。 作为医卫界政协委员，谢良地今年将围绕"加强慢病防控基层建设"提出建议，涵盖政策协同、资源下 沉、中西医并重、人才培养等多方面。"慢病管理是一场持久战，需要政府、医院、媒体、公众等力量 共同参与。"谢良地说，自己的角色就像一名"桥梁工"——连接政策与落实、专业与普及、治疗与预 防 ...

提出高质量提案，关键在深入调查研究。谢良地来自闽东山村，乡村始终是他关注的焦点，每年他有近三分之一的时间奔走在基层。 一身白大褂，一边耐心询问村民的血压情况，一边在笔记本上记录基层诊疗中的所思所想——在福建不少地方的县医院、基层卫生院，经常能看到全国政协 委员、福建省高血压研究所所长谢良地的身影。对他来说，这既是临床工作，也是作为政协委员的职责。 "高血压不是孤立的疾病，它是一种生活方式病。"谢良地说。我国高血压患者基数庞大，但高血压的知晓率、治疗率、控制率相对较低。作为一名从事高血 压防治工作数十年的临床医生，他的履职工作始终围绕"如何让更多人远离高血压"展开。 在2025年全国两会上，谢良地呼吁为高血压防控打造专业平台，培养专职队伍。"没有专科，医生就没有'阵地'；没有专业队伍，防控就难成体系。"在他看 来，高血压防治涉及预防、筛查、诊断、治疗、康复等多个环节，必须有一支专业的队伍"盯得住、管得全"。 2025 年世界高血压日，福建省高血压研究所所长谢良地为群众义诊。（受访者供图） 基于对基层情况的深入了解，谢良地将履职的着力点放在如何织密慢病防控这张网上。一年来，谢良地走进南平浦城、宁德周宁、龙岩上杭等 ...

一身白大褂，一边耐心询问村民的血压情况，一边在笔记本上记录基层诊疗中的所思所想——在福建不 少地方的县医院、基层卫生院，经常能看到全国政协委员、福建省高血压研究所所长谢良地的身影。对 他来说，这既是临床工作，也是作为政协委员的职责。 ●新华社记者 黄景鸿 吴剑锋 作为医卫界政协委员，谢良地今年将围绕"加强慢病防控基层建设"提出建议，涵盖政策协同、资源下 沉、中西医并重、人才培养等多方面。"慢病管理是一场持久战，需要政府、医院、媒体、公众等力量 共同参与。"谢良地说，自己的角色就像一名"桥梁工"——连接政策与落实、专业与普及、治疗与预 防。 "让更多人知晓高血压、防控高血压，这件事本身就是在为国家减负、为家庭造福。"谢良地说，作为医 生和政协委员，他最大的心愿，就是通过一点一滴的努力，把慢病防控的"网"织得更密、更牢。 【记者手记】 采访谢良地委员，印象最深的是他话语中那份"接地气"的务实。他不仅是高血压防治领域的专家，更是 长期扎根一线的观察者与行动者。他的履职，始终围绕"问题从哪里来，就到哪里去找答案"——门诊、 基层卫生院、患者家中，都是他的调研现场。 "高血压不是孤立的疾病，它是一种生活方式病。"谢良地 ...

Core Insights - The 2025 Life Science Conference, themed "Integration of Medicine and Engineering to Promote High-Quality Chronic Disease Prevention and Control," will be held in Hangzhou from December 5 to 7, 2025, aiming to shift from a disease-centered approach to a health-centered one, in line with the "Healthy China 2030" strategy [1] - The conference aligns with the goals of the 14th Five-Year Plan and the upcoming 15th Five-Year Plan, emphasizing the importance of technological self-reliance and innovation in driving economic and social development [1] Group 1: Conference Objectives and Themes - The conference aims to accelerate the integration of biology, information, and medical technology, establishing a comprehensive chronic disease prevention and control system [1] - It focuses on the future trends in medical and life sciences, the intersection of medicine and engineering, and the transformation of clinical results into practical applications [2] Group 2: Key Activities and Awards - The opening ceremony featured significant events, including the 12th Shulan Medical Award, which recognized prominent figures in the life sciences, and the 2025 SATOL Life Science Innovation and Entrepreneurship Leaders Award [3] - The Shulan Medical Award has become a reputable recognition in the life sciences field, promoting new talent and educational development [3] Group 3: Industry Collaboration and Innovation - The Chinese Medical Association's Organ Transplantation Physician Branch, in collaboration with the National Liver Transplant Quality Control Center, initiated a project to develop an "AI-based organ transplantation diagnostic model" to enhance industry quality through advanced technology [4] - The conference facilitated discussions among top experts and young scientists on the latest research in life sciences, addressing technological bottlenecks in chronic disease prevention and proposing solutions [5] Group 4: Long-term Industry Impact - The successful hosting of the conference established a high-end platform for global life science exchange and collaboration, embedding the concept of medical-engineering integration into chronic disease prevention [6] - This initiative is expected to accelerate the clustering of the life and health industry in Zhejiang, promoting the transformation of innovative results into clinical applications and contributing to the goals of a healthy China [6]

Core Insights - The 2025 Life Science Conference, themed "Integration of Medicine and Engineering to Promote High-Quality Chronic Disease Prevention and Control," will be held in Hangzhou from December 5 to 7, 2025, aiming to shift from a disease-centered approach to a health-centered one, accelerating the integration of biology, information, and medical technology [1][2] - The conference aligns with the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan," emphasizing the enhancement of technological self-reliance and innovation in the life sciences sector [2][3] Group 1: Conference Objectives and Themes - The conference aims to promote the integration of medical and engineering fields, focusing on chronic disease prevention and control, and fostering a comprehensive system for prevention, diagnosis, and rehabilitation [1][4] - It seeks to facilitate the transformation of clinical results and the development of major projects in Zhejiang, contributing to the upgrade of the regional life and health industry [2][4] Group 2: Key Activities and Awards - The opening ceremony featured significant events, including the 12th Shulan Medical Award, which recognized prominent figures in the life sciences, enhancing the credibility of the sector [5][7] - The 2025 SATOL Life Science Innovation and Entrepreneurship Leaders Award ceremony highlighted ten outstanding scientists, reinforcing the importance of innovation and entrepreneurship in the life sciences [7] Group 3: Expert Discussions and Innovations - The conference gathered top experts and young scientists to discuss the latest research in life sciences, addressing technological bottlenecks in chronic disease prevention and exploring solutions [8] - Discussions focused on leveraging artificial intelligence and biomaterials to optimize chronic disease diagnosis and treatment processes, aiming to create a comprehensive health management system [8] Group 4: Long-term Industry Impact - The successful hosting of the conference established a high-end platform for global life science collaboration, embedding the concept of medical-engineering integration into chronic disease prevention [9] - This initiative is a crucial step for Zhejiang in implementing the strategy of technological self-reliance, accelerating the clustering of the life and health industry, and contributing to the global health agenda [9]

Core Viewpoint - The article highlights the initiative to promote exemplary experiences and innovative measures in hospital construction and high-quality development across various medical institutions in China, aiming to enhance public awareness of healthcare reform outcomes through a series of live broadcasts featuring hospital directors sharing their insights [1]. Group 1: Event Details - A live broadcast featuring Sun Daqiang, the director of Tianjin Chest Hospital, will take place on November 19 from 10:00 to 11:00, focusing on the topic of "Using Scientific Research to Address Chronic Disease Prevention and Promote High-Quality Development of Public Hospitals" [1]. Group 2: Guest Profile - Sun Daqiang is a distinguished figure in the medical field, serving as the director of Tianjin Chest Hospital, a chief physician, professor, and doctoral supervisor. He holds several leadership positions in various medical associations, including the Chairman of the Thoracic Surgery Branch of Tianjin Medical Association [2]. Group 3: Viewing Instructions - To watch the program, users can download the People's Good Doctor App and access the live broadcast through the homepage carousel [3]. Additionally, following the People's Health public WeChat account provides another avenue for accessing the app and the program [4].

Core Viewpoint - The China International Import Expo (CIIE) provides a significant platform for multinational companies to deepen their engagement in the Chinese market and share development opportunities [1] Group 1: Company Initiatives - AstraZeneca hosted over 30 events at the CIIE and announced multiple significant investments and collaborations [1] - During the "Chronic Disease Health Day" event, AstraZeneca focused on various health issues including hypertension, diabetes, severe asthma, and chronic obstructive pulmonary disease [1] - AstraZeneca established a strategic partnership with the Suzhou Industrial Park Oriental Huaxia Cardiovascular Health Research Institute to support the construction of a "China Cardiomyopathy Diagnosis and Treatment Collaborative Network" aimed at improving screening and treatment rates for cardiomyopathy patients [1] Group 2: Health Strategy - The "Healthy China 2030" plan emphasizes the importance of early diagnosis, treatment, and rehabilitation to achieve the goal of "national health" [1] - AstraZeneca is collaborating with various partners to build a comprehensive management system for diseases, enhancing the standardization of diagnosis and treatment to ensure quality medical services reach a broader population [1]

Core Insights - The event during the China International Import Expo focused on the importance of public awareness and prevention of chronic kidney diseases, particularly IgA nephropathy, which is a significant health concern in China [1][5] - The World Health Organization has classified chronic kidney disease as a major non-communicable disease that requires urgent attention [1] - The discussion highlighted the need for improved diagnosis, treatment awareness, and long-term management strategies for IgA nephropathy patients [2][5] Group 1: Challenges in IgA Nephropathy Management - IgA nephropathy faces three main challenges: timely and accurate diagnosis, insufficient understanding of treatment goals, and difficulties in long-term disease progression management [2] - There is a call for innovative treatment solutions and enhanced public health education to improve patient outcomes and awareness [2][5] Group 2: Role of Education and Awareness - Experts emphasized the necessity of comprehensive public education on kidney health, addressing common misconceptions and promoting accurate information [2][5] - The importance of utilizing authoritative media and new technologies, such as AI, to expand the reach and effectiveness of health education was discussed [5] Group 3: Corporate Responsibility - Companies like Novartis recognize their responsibility in providing high-quality, scientific information to patients and are committed to social responsibility in the kidney disease sector [5]

Group 1: Health Planning and Chronic Disease Management - The National Health Commission aims to increase the average life expectancy of Chinese residents from 79 years in 2024 to around 80 years within five years, supported by chronic disease prevention efforts [1] - Chronic diseases such as cardiovascular diseases and cancer are on the rise, with over 80% of total deaths attributed to these conditions, posing significant health and economic challenges [1] - The government has integrated chronic disease prevention into national strategy, focusing on obesity management as a key area for policy intervention [3][4] Group 2: Market Dynamics and Opportunities - The obesity treatment market is becoming increasingly competitive, with major pharmaceutical companies like Novo Nordisk and Eli Lilly leading with their GLP-1 products, while domestic companies are also advancing their offerings [5][8] - The CGM market in China is projected to grow from approximately 1.7 billion yuan in 2020 to 17.9 billion yuan by 2030, indicating a strong demand for diabetes management solutions [5] - The global market for obesity and metabolic drugs is expected to exceed $100 billion by 2030, with GLP-1 drugs being a significant growth driver [5] Group 3: Distribution and Accessibility - The retail market for GLP-1 products is expanding, with companies like Novo Nordisk and Eli Lilly actively pursuing this channel due to high entry barriers in hospital settings [6] - Online channels, particularly platforms like JD Health, are becoming dominant in the weight loss drug market, accounting for over 70% of sales, significantly outpacing traditional channels [6][7] - The shift from passive to proactive health management is driving growth in home medical devices, with a notable increase in demand for self-monitoring tools [7] Group 4: Innovation and Competitive Landscape - The GLP-1 market is characterized by a "dual oligopoly" with Novo Nordisk and Eli Lilly holding significant market share, but local companies are intensifying competition through differentiated product offerings [8][9] - Domestic firms are focusing on unmet clinical needs and expanding indications to build long-term competitiveness, moving the industry from a "follower" to a "leader" position [9] - Innovations in drug delivery methods and combination therapies are being explored by local companies to enhance their market presence and address diverse patient needs [9]

Core Insights - The University of Washington's IHME director Christopher Murray highlighted that China has the potential to achieve significant breakthroughs in the prevention of hypertension and smoking-related diseases within the next five to ten years through enhanced primary healthcare and strict tobacco control policies [2][3] Group 1: Disease Burden and Prevention Strategies - Non-communicable diseases (NCDs) currently account for nearly two-thirds of global mortality and morbidity, with ischemic heart disease, stroke, and diabetes being the leading causes [2] - Controlling major risk factors such as lowering blood sugar levels and managing high body mass index (BMI) could prevent nearly half of deaths and disabilities [2] Group 2: Focus Areas for China - Addressing hypertension is identified as a high-potential area for disease prevention in China, with effective strategies validated through randomized trials, such as promoting potassium chloride as a partial substitute for sodium chloride [3] - The combination therapy provided through primary healthcare has proven to be very effective in managing hypertension [3] - Smoking is another critical risk factor, with the WHO's MPOWER policy package suggesting measures like increasing tobacco taxes, banning tobacco advertising, and enforcing public smoking bans to effectively reduce smoking rates [3] Group 3: Future Disease Patterns - The future disease landscape in China is expected to be dominated by obesity-related diseases (such as diabetes and chronic kidney disease) as well as diseases related to smoking and hypertension [3] - An often-overlooked issue is falls among the elderly, which can be addressed through effective interventions to alleviate the disease burden in this demographic [3]